We hope this work opens new possibilities for targeted therapies in MM. There is a lot of biological validation that needs to be done using these scRNAseq data as a blueprint. More to come! #plasmacell #mmsm

To investigate EndMT features, we tested JQ1, a BET inhibitor known to affect mesenchymal features. However, JQ1 didn’t reverse mesenchymal markers in MM ECs, suggesting that MM ECs may require different, more complex intervention strategies. @JunQiLab

Fascinatingly, MM ECs are highly interactive within the bone marrow. We found enhanced cell–cell signaling, particularly between ECs and mesenchymal stem cells (MSCs), which likely reinforce MM cell survival and growth.

To dive deeper, we developed a new protocol to isolate & culture ECs from MM patients' bone marrow, allowing us to study these cells’ pro-tumor activities in vitro. This model opens avenues for testing therapies directly on MM-derived ECs!

Using data from @NatImmunol paper by @mdejong.bsky.social et al. we identified unique pathway activations in MM-derived ECs, setting them apart from healthy controls. Key pathways? Epithelial–mesenchymal plasticity (EMP) and TGF-beta. MM microenvironemnt seems very complex #scRNAseq

Excited to announce our latest study, where we explored the role of endothelial cells (ECs) and progenitors in #MultipleMyeloma #mmsm (MM) progression! We show how MM bone marrow ECs differ transcriptionally and functionally from those in healthy donors. #hematology #oncology 🧵